A synthetic peptide as a novel anticryptococcal agent

Cellular Microbiology

Volumn 6, Issue 10, 2004, Pages 953-961

  Cenci, Elio ^a   Bistoni, Francesco ^a   Mencacci, Antonella ^a   Perito, Stefano ^a   Magliani, Walter ^b   Conti, Stefania ^b   Polonelli, Luciano ^b   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BETA GLUCAN; KILLER DECAPEPTIDE; PROTEINASE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UREASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CELL WALL; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFICACY; DRUG SYNTHESIS; EFFECTOR CELL; ENZYME ACTIVITY; FEMALE; FUNGAL CELL; FUNGAL VIRULENCE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANIMALS; ANTIFUNGAL AGENTS; BETA-GLUCANS; CANDIDA ALBICANS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MACROPHAGES; MELANINS; MICE; MICE, INBRED BALB C; NEUTROPHILS; PEPTIDES; POLYSACCHARIDES; SURVIVAL RATE; VIRULENCE FACTORS;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 4544250583     PISSN: 14625814     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1462-5822.2004.00413.x     Document Type: Article

References (49)

1. Aoki, S., Ito-Kuwa, S., Nakamura, K., Ninomiya, K., and Vidotto, V. (1994) Extracellular proteolytic activity of Cryptococcus neoformans. Mycopathologia 128: 143-150.
2. Beninati, C., Oggioni, M.R., Boccanera, M., Spinosa, M.R., Maggi, T., Conti, S., et al. (2000) Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat Biotechnol 18: 1060-1064.
3. Blackstock, R., Buchanan, K.L., Cherniak, R., Mitchell, T.G., Wong, B., Bartiss, A., et al. (1999) Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia 147: 1-11.
4. Casadevall, A., and Perfect, J.R. (1998) Human cryptococcosis. In Cryptococcus neoformans. Casadevall, A., and Perfect, J.R., (eds). Washington, DC: American Society for Microbiology Press, pp. 407-456.
5. Cassone, A., Conti, S., De Bernardis, F., and Polonelli, L. (1997) Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol Today 18: 164-169.
6. Cenci, E., Mencacci, A., Spreca, A., Montagnoli, C., Bacci, A., Perruccio, K., et al. (2002) Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun 70: 2375-2382.
7. Chen, L.C., Blank, E.S., and Casadevall, A. (1996) Extracellular proteinase activity of Cryptococcus neoformans. Clin Diagn Laboratory Immunol 3: 570-575.
8. Chen, S.C., Muller, M., Zhou, J.Z., Wright, L.C., and Sorrell, T.C. (1997) Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J Infect Dis 175: 414-420.
9. Conti, S., Fanti, F., Magliani, W., Gerloni, M., Bertolotti, D., Salati, A., et al. (1998) Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. J Infect Dis 177: 807-811.
10. Conti, S., Magliani, W., Arseni, S.E., Dieci, E., Frazzi, R., Salati, A., et al. (2000) In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic-resistant gram-positive cocci. Mol Med 6: 613-619.
11. Cox, M.G., Mukherjee, J., Cole, G.T., Casadevall, A., and Perfect, J.R. (2000) Urease as a virulence factor in experimental cryptococcosis. Infect Immun 68: 443-448.
12. De Bernardis, F, Sullivan, P.A., and Cassone, A. (2001) Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 39: 303-313.
13. Echevarria, A., Durante, A.G., Arechaval, A., and Negroni, R. (2002) Comparative study of two culture media for the detection of phospholipase activity of Candida albicans and Cryptococcus neoformans strains. Rev Iberoam Micol 19: 95-98.
14. Franzot, S.P., Mukherjee, J., Cherniak, R., Chen, L.C., Hamdan, J.S., and Casadevall, A. (1998) Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun 66: 89-97.
15. Friese, G., Discher, T., Fussle, R., Schmalreck, A., and Lohmeyer, J. (2001) Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 23: 2344-2345.
16. Gallis, H.A., Berman, R.A., Cate, T.R., Hamilton, J.D., Gunnells, J.C., and Stickel, D.L. (1975) Fungal infection following renal transplantation. Arch Intern Med 135: 1163-1172.
17. Ghannoum, M.A. (2000) Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 13: 122-143.
18. Gomez, B.L., and Nosanchuk, J.D. (2003) Melanin and fungi. Curr Opin Infect Dis 16: 91-96.
19. Guyard, C., Dehecq, E., Tissier, J.P., Polonelli, L., Dei-Cas, E., Cailliez, J.C., and Menozzi, F.D. (2002a) Involvement of β-glucans in the wide-spectrum antimicrobial activity of Williopsis saturnus var. mrakii MUCL 41968 killer toxin. Mol Med 8: 686-694.
20. Guyard, C., Séguy, N., Cailliez, J.C., Drobecq, H., Polonelli, L., Dei-Cas, E., et al. (2002b) Characterization of a Williopsis saturnus var. mrakii high molecular weight secreted killer toxin with broad-spectrum antimicrobial activity. J Antimicrob Chemother 49: 961-971.
21. James, P.G., Cherniak, R., Jones, R.G., Stortz, C.A., and Reiss, E. (1990) Cell-wall glucans of Cryptococcus neoformans Cap 67. Carbohydr Res 198: 23-38.
22. John, G.T., Mathew, M., Snehalatha, E., Anandi, V., Date, A., Jacob, C.K., and Shastry, J.C. (1994) Cryptococcosis in renal allograft recipients. Transplantation 58: 855-856.
23. Levitz, S.M., and Diamond, R.D. (1985) A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J Infect Dis 152: 938-945.
24. Magliani, W., Conti, S., Arseni, S., Frazzi, R., Salati, A., and Polonelli, L. (2001) Killer anti-idiotypes in the control of fungal infections. Curr Opin Invest Drugs 2: 477-479.
25. Magliani, W., Conti, S., Gerloni, M., Bertolotti, D., and Polonelli, L. (1997a) Yeast killer systems. Clin Microbiol Rev 10: 369-400.
26. Magliani, W., Conti, S., De Bernardis, F., Gerloni, M., Bertolotti, D., Mozzoni, P., et al. (1997b) Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat Biotechnol 15: 155-158.
27. Monari, C., Kozel, T.R., Bistoni, F., and Vecchiarelli, A. (2002) Modulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans. Infect Immun 70: 3363-3370.
28. Naglik, J.R., Challacombe, S.J., and Hube, B. (2003) Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67: 400-428.
29. Oggioni, M.R., Beninati, C., Boccanera, M., Medaglini, D., Spinosa, M.R., Maggi, T., et al. (2001) Recombinant Streptococcus gordonii for mucosal delivery of a scFv microbicidal antibody. Int Rev Immunol 20: 275-287.
30. Perfect, J.R., and Casadevall, A. (2002) Cryptococcosis. Infect Dis Clin North Am 16: 837-874.
31. Polonelli, L., and Morace, G. (1987) Production and characterization of yeast killer toxin monoclonal antibodies. J Clin Microbiol 25: 460-462.
32. Polonelli, L., and Morace, G. (1988) Yeast killer toxin-like anti-idiotypic antibodies. J Clin Microbiol 26: 602-604.
33. Polonelli, L., Conti, S., De Bernardis, F., Gerloni, M., Magliani, W., Castagnola, M., et al. (1991) 'Antibiobodies': antibiotic-like anti-idiotypic antibodies. J Med Vet Mycol 29: 235-242.
34. Polonelli, L., Lorenzini, R., De Bernardis, F., Gerloni, M., Conti, S., Morace, G., et al. (1993) Idyotipic vaccination: Immunoprotection mediated by anti-idyotipic antibodies with antibiotic activity. Scand J Immunol 37: 105-110.
35. Polonelli, L., De Bernardis, F., Conti, S., Boccanera, M., Gerloni, M., Morace, G., et al. (1994) Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol 152: 3175-3182.
36. Polonelli, L., De Bernardis, F., Conti, S., Boccanera, M., Magliani, W., Gerloni, M., et al. (1996) Human natural yeast killer toxin-like candidacidal antibodies. J Immunol 156: 1880-1885.
37. Polonelli, L., Séguy, N., Conti, S., Gerloni, M., Bertolotti, D., Cantelli, C., et al. (1997) Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin Diagn Laboratory Immunol 4: 142-146.
38. Polonelli, L., Magliani, W., Conti, S., Bracci, L., Lozzi, L., Neri, P., et al. (2003) Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 71: 6205-6212.
39. Powderly, W.G. (1996) Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 22: 119-123.
40. Reese, A.J., and Doering, T.L. (2003) Cell wall alpha-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol 50: 1401-1409.
41. Retini, C., Vecchiarelli, A., Monari, C., Bistoni, F., and Kozel, T.R. (1998) Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun 66: 664-669.
42. Savoia, D., Avanzini, C., Conti, S., Magliani, W., Frazzi, R., and Polonelli, L. (2002) In vitro leishmanicidal activity of a monoclonal antibody mimicking a yeast killer toxin. J Eukaryot Microbiol 49: 319-323.
43. Schmiel, D.H., and Miller, V.L. (1999) Bacterial phospholipases and pathogenesis. Microbes Infect 1: 1103-1112.
44. Séguy, N., Polonelli, L., Dei-Cas, E., and Cailliez, J.C. (1997) Monoclonal killer toxin-like antiidiotypic antibodies to control rat-pneumocystosis. J Eukaryot Microbiol 44: 375.
45. Séguy, N., Polonelli, L., Dei-Cas, E., and Cailliez, J.C. (1998) Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis. FEMS Immunol Med Microbiol 22: 145-149.
46. Selitrennikoff, C.P., and Nakata, M. (2003) New cell wall targets for antifungal drugs. Curr Opin Invest Drug 4: 200-205.
47. Sentandreu, R., Herrero, E., Elorza, M.V., Rico, H., and Pastor, J. (1983) Synthesis and assembly of wall polymers on regenerating yeast protoplasts. Experientia 46: 187-195.
48. Thompson, J.R., Douglas, C.M., Li, W., Jue, C.K., Pramanik, B., et al. (1999) A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol 181: 444-453.
49. Vecchiarelli, A. (2000) Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol 38: 407-417.